RA0518

antibody from Oursmab

Targeting: MUC5AC MUC5

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0518

Provider

Oursmab

Product name

Ensituximab (Biosimilar Reference Antibody) (MUC5AC)

Antibody type

Monoclonal

Description

Ensituximab (also known as NEO-102 and NPC-1C) is a novel, chimeric immunoglobulin G1 (IgG1) monoclonal antibody developed as a biological therapy for patients with pancreatic and colorectal cancers. It was designed to bind to a set of human colorectal and pancreatic carcinoma-associated antigens. The exact molecular target(s) of ensituximab remain(s) uncertain, representing a unique and challenging aspect of its development. While initially described as targeting undefined tumor-associated antigens, subsequent research suggested that its primary target might be the specific mucin protein MUC5AC. The intended mechanism of action involves binding to these antigens on the surface of cancer cells, potentially inhibiting tumor-promoting functions and marking the cells for immune-mediated destruction (e.g., via ADCC).

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.